Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ: SABS) with a Buy rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage